Csl Limited (CSLLY) 33.8200 $CSLLY
Plasma Fractionation Market worth $25,383.4 Million by 2019 - Key Player of Market Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy)
M2 - Wed Jan 21, 4:40AM CST
According to the new market research report The "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019", published by MarketsandMarkets, the Plasma Fractionation Market is expected to reach nearly $25,383.4 Million by 2019, growing at a CAGR of 8.9% from 2014 to 2019.
GRFS: 34.65 (+0.28)
Allergic Asthma - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28fk26/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2013" report to their offering. 'Allergic Asthma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Asthma. Allergic Asthma - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergic Asthma. - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Asthma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Ablynx NV - Dainippon Sumitomo Pharma Co., Ltd. - Infinity Pharmaceuticals, Inc. - Novartis AG - ALK-Abello A/S - ASKA Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Portola Pharmaceuticals, Inc. - CSL Limited - Stallergenes S.A. - Cytos Biotechnology AG - Panacea Biotec Limited - Marinomed Biotechnologie GmbH - Allergopharma Joachim Ganzer KG - Funxional Therapeutics Ltd - AIM Therapeutics Inc. - Asmacure Ltee - IXO Therapeutics Limited - Protectimmun GmbH - Visionary Pharmaceuticals, Inc. - Trident Pharmaceuticals, Inc. - sterna biologicals Gmbh & Co KG - S-TARget therapeutics GmbH - PanPharmaceuticals USA, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/28...gic_asthma
PTLA: 34.96 (+3.13), AZN: 69.96 (+0.20), INFI: 15.13 (+0.55), NVS: 102.20 (-0.17)
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.85 (+0.05), LXRX: 0.89 (unch), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06)
CSL Issues "Our Corporate Responsibility 2014" Report
PR Newswire - Thu Dec 04, 8:00AM CST
CSL Behring's parent company CSL Limited (ASX: CSL) has issued its annual corporate responsibility report - "Our Corporate Responsibility 2014." The report details the global biopharmaceutical company's performance across key priority areas from July 1, 2013 through June 30, 2014 - recording another strong performance led by CSL Behring.
CSL: 94.14 (-0.09)
Atherosclerosis - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/xjlf7c/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atherosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to ehance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences, Inc. - Ache Laboratorios Farmaceuticos S/A - advanceCor GmbH - AFFiRiS AG - Arisaph Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - AtheroNova Inc. - AuraSense Therapeutics, LLC - Bayer AG - Boehringer Ingelheim GmbH - Bridge Bioresearch Plc - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - ChemoCentryx, Inc. - CIMAB S.A. - CSL Limited - DoNatur GmbH - Dr. Reddy's Laboratories Limited - Dybly AG - GlaxoSmithKline plc - Isis Pharmaceuticals, Inc. - Johnson & Johnson - KineMed, Inc. - Kowa Company, Ltd. - Lead Discovery Center GmbH - MedImmune, LLC - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/xj...osclerosis
KNMD: (), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), AZN: 69.96 (+0.20), CCXI: 7.85 (+0.04)
Stop Worrying About Ebola: This is a Much More Pressing Concern
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 22, 2:04PM CST
Source: European Commission DG ECHO via Flickr . Despite there being just four reported cases of Ebola in the U.S. this year, including one tragic death, it's been a disease that's garnered months of attention from the American public and...
AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), NVS: 102.20 (-0.17)
CSL Limited Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
PR Newswire - Wed Nov 12, 7:00AM CST
CSL Limited today announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a novel formulation of apolipoprotein A-I (apoA-I). Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture. This represents a new approach to reduce the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack.
Global Polyneuropathies Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btffr4/polyneuropathies) has announced the addition of the "Polyneuropathies Global Clinical Trials Review, H2, 2014" report to their offering. Polyneuropathies Global Clinical Trials Review, H2, 2014" provides data on the Polyneuropathies clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polyneuropathies. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polyneuropathies. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polyneuropathies Therapeutics Clinical Trials - Pfizer Inc. - NeurogesX, Inc. - CSL Limited - Novartis AG - LFB S.A. - Grifols, S.A. - Biogen Idec Inc. - Eisai Co., Ltd. - E. Merck KG - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - Odense University Hospital - National Center for Research Resources - Assistance Publique - Hopitaux de Paris - Aarhus University - Erasmus MC - Skane University Hospital - The University of New South Wales - Medical University of Vienna - Oregon Health & Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/bt...uropathies
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Global Neuropathy Clinical Trials Therapeutics Review, H2, 2014 - Espy the Commercial Landscape of the Top 10 Major Universities & Companies
M2 - Tue Oct 28, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl4t37/neuropathy_global) has announced the addition of the "Neuropathy Global Clinical Trials Review, H2, 2014" report to their offering. Neuropathy Global Clinical Trials Review, H2, 2014" provides data on the Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Pfizer Inc. - Sanofi - NeurogesX, Inc. - GW Pharmaceuticals plc - Sumitomo Chemical Company, Limited - CSL Limited - Grunenthal GmbH - Eli Lilly and Company - Baxter International Inc. - Astellas Pharma Inc. Top Institutes / Government - University of Texas M. D. Anderson Cancer Center - National Taiwan University Hospital - U.S. Department of Veterans Affairs - Odense University Hospital - Columbia University - The National Institute of Allergy and Infectious Diseases - Washington University School of Medicine - National Center for Research Resources - Rigshospitalet - Oregon Health & Science University For more information visit http://www.researchandmarkets.com/research/cl...thy_global
BAX: 70.39 (+0.31), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03)
Novartis selling flu vaccine unit to CSL for $275M
AP - Mon Oct 27, 11:05AM CDT
NEW YORK (AP) — Australian drugmaker CSL Ltd. said Monday it will buy Novartis' flu vaccine business for $275 million.
CSL: 94.14 (-0.09), NVS: 102.20 (-0.17)
CSL to acquire Novartis' influenza vaccine business
PR Newswire - Mon Oct 27, 7:20AM CDT
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.
CSL: 94.14 (-0.09)
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014: Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals & Companies
M2 - Fri Aug 15, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2fqtrx/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" report to their offering. "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Guillain-Barre Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Guillain-Barre Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Guillain-Barre Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Harvard Pilgrim Health Care, Inc. - GlaxoSmithKline plc - CSL Limited Clinical Trial Overview of Top Institutes / Government - Erasmus MC - FDA Office of Orphan Products Development - Chhatrapati Shahuji Maharaj Medical University - Mansoura University - University Medical Centre Ljubljana - University of Versailles - University of Cologne - NHS Greater Glasgow and Clyde - National Taiwan University Hospital For more information visit http://www.researchandmarkets.com/research/2f...llainbarre
GSK: 47.94 (+1.99)
Global Blood Plasma Market Report: 2014 Edition
M2 - Fri Jul 11, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v86kh7/global_blood) has announced the addition of the "Global Blood Plasma Market Report: 2014 Edition" report to their offering. With the swift changes and advancement in biomedical/healthcare technology, the healthcare/pharmaceutical/therapeutic industry is becoming ever more competitive. Also, increasing incidences of health related issues owing to changing lifestyles is augmenting the blood plasma industry's growth. In order to address the rising medical needs related to blood disorders such as autoimmune diseases and liver function impairment among others, market players are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. The report, Global Blood Plasma Market presents different facets of the global blood plasma market with a focus on sub-markets like IVIG, albumin and hemophilia market. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is presented. The market remains highly concentrated and is dominated by a handful of players including CSL, Grifols, Baxter and Octapharma. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. Key Topics Covered: 1. Overview 2. Blood Plasma Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Baxter International Inc. - CSL Limited - Grifols - Octapharma AG For more information visit http://www.researchandmarkets.com/research/v8...obal_blood
BAX: 70.39 (+0.31)
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
BIIB: 391.66 (-0.45), NVS: 102.20 (-0.17)
Plasma Fractionation Market worth $25,383.4 Million by 2019 - Key Player of Market Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy)
M2 - Wed Jan 21, 4:40AM CST
According to the new market research report The "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019", published by MarketsandMarkets, the Plasma Fractionation Market is expected to reach nearly $25,383.4 Million by 2019, growing at a CAGR of 8.9% from 2014 to 2019.
GRFS: 34.65 (+0.28)
Allergic Asthma - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28fk26/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2013" report to their offering. 'Allergic Asthma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Asthma. Allergic Asthma - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergic Asthma. - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Asthma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Ablynx NV - Dainippon Sumitomo Pharma Co., Ltd. - Infinity Pharmaceuticals, Inc. - Novartis AG - ALK-Abello A/S - ASKA Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Portola Pharmaceuticals, Inc. - CSL Limited - Stallergenes S.A. - Cytos Biotechnology AG - Panacea Biotec Limited - Marinomed Biotechnologie GmbH - Allergopharma Joachim Ganzer KG - Funxional Therapeutics Ltd - AIM Therapeutics Inc. - Asmacure Ltee - IXO Therapeutics Limited - Protectimmun GmbH - Visionary Pharmaceuticals, Inc. - Trident Pharmaceuticals, Inc. - sterna biologicals Gmbh & Co KG - S-TARget therapeutics GmbH - PanPharmaceuticals USA, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/28...gic_asthma
PTLA: 34.96 (+3.13), AZN: 69.96 (+0.20), INFI: 15.13 (+0.55), NVS: 102.20 (-0.17)
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.85 (+0.05), LXRX: 0.89 (unch), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06)
CSL Issues "Our Corporate Responsibility 2014" Report
PR Newswire - Thu Dec 04, 8:00AM CST
CSL Behring's parent company CSL Limited (ASX: CSL) has issued its annual corporate responsibility report - "Our Corporate Responsibility 2014." The report details the global biopharmaceutical company's performance across key priority areas from July 1, 2013 through June 30, 2014 - recording another strong performance led by CSL Behring.
CSL: 94.14 (-0.09)
Atherosclerosis - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/xjlf7c/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atherosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to ehance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences, Inc. - Ache Laboratorios Farmaceuticos S/A - advanceCor GmbH - AFFiRiS AG - Arisaph Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - AtheroNova Inc. - AuraSense Therapeutics, LLC - Bayer AG - Boehringer Ingelheim GmbH - Bridge Bioresearch Plc - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - ChemoCentryx, Inc. - CIMAB S.A. - CSL Limited - DoNatur GmbH - Dr. Reddy's Laboratories Limited - Dybly AG - GlaxoSmithKline plc - Isis Pharmaceuticals, Inc. - Johnson & Johnson - KineMed, Inc. - Kowa Company, Ltd. - Lead Discovery Center GmbH - MedImmune, LLC - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/xj...osclerosis
KNMD: (), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), AZN: 69.96 (+0.20), CCXI: 7.85 (+0.04)
Stop Worrying About Ebola: This is a Much More Pressing Concern
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 22, 2:04PM CST
Source: European Commission DG ECHO via Flickr . Despite there being just four reported cases of Ebola in the U.S. this year, including one tragic death, it's been a disease that's garnered months of attention from the American public and...
AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), NVS: 102.20 (-0.17)
CSL Limited Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
PR Newswire - Wed Nov 12, 7:00AM CST
CSL Limited today announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a novel formulation of apolipoprotein A-I (apoA-I). Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture. This represents a new approach to reduce the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack.
Global Polyneuropathies Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btffr4/polyneuropathies) has announced the addition of the "Polyneuropathies Global Clinical Trials Review, H2, 2014" report to their offering. Polyneuropathies Global Clinical Trials Review, H2, 2014" provides data on the Polyneuropathies clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polyneuropathies. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polyneuropathies. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Polyneuropathies Therapeutics Clinical Trials - Pfizer Inc. - NeurogesX, Inc. - CSL Limited - Novartis AG - LFB S.A. - Grifols, S.A. - Biogen Idec Inc. - Eisai Co., Ltd. - E. Merck KG - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - Odense University Hospital - National Center for Research Resources - Assistance Publique - Hopitaux de Paris - Aarhus University - Erasmus MC - Skane University Hospital - The University of New South Wales - Medical University of Vienna - Oregon Health & Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/bt...uropathies
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Global Neuropathy Clinical Trials Therapeutics Review, H2, 2014 - Espy the Commercial Landscape of the Top 10 Major Universities & Companies
M2 - Tue Oct 28, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl4t37/neuropathy_global) has announced the addition of the "Neuropathy Global Clinical Trials Review, H2, 2014" report to their offering. Neuropathy Global Clinical Trials Review, H2, 2014" provides data on the Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Pfizer Inc. - Sanofi - NeurogesX, Inc. - GW Pharmaceuticals plc - Sumitomo Chemical Company, Limited - CSL Limited - Grunenthal GmbH - Eli Lilly and Company - Baxter International Inc. - Astellas Pharma Inc. Top Institutes / Government - University of Texas M. D. Anderson Cancer Center - National Taiwan University Hospital - U.S. Department of Veterans Affairs - Odense University Hospital - Columbia University - The National Institute of Allergy and Infectious Diseases - Washington University School of Medicine - National Center for Research Resources - Rigshospitalet - Oregon Health & Science University For more information visit http://www.researchandmarkets.com/research/cl...thy_global
BAX: 70.39 (+0.31), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03)
Novartis selling flu vaccine unit to CSL for $275M
AP - Mon Oct 27, 11:05AM CDT
NEW YORK (AP) — Australian drugmaker CSL Ltd. said Monday it will buy Novartis' flu vaccine business for $275 million.
CSL: 94.14 (-0.09), NVS: 102.20 (-0.17)
CSL to acquire Novartis' influenza vaccine business
PR Newswire - Mon Oct 27, 7:20AM CDT
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.
CSL: 94.14 (-0.09)
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014: Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals & Companies
M2 - Fri Aug 15, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2fqtrx/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" report to their offering. "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Guillain-Barre Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Guillain-Barre Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Guillain-Barre Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Harvard Pilgrim Health Care, Inc. - GlaxoSmithKline plc - CSL Limited Clinical Trial Overview of Top Institutes / Government - Erasmus MC - FDA Office of Orphan Products Development - Chhatrapati Shahuji Maharaj Medical University - Mansoura University - University Medical Centre Ljubljana - University of Versailles - University of Cologne - NHS Greater Glasgow and Clyde - National Taiwan University Hospital For more information visit http://www.researchandmarkets.com/research/2f...llainbarre
GSK: 47.94 (+1.99)
Global Blood Plasma Market Report: 2014 Edition
M2 - Fri Jul 11, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v86kh7/global_blood) has announced the addition of the "Global Blood Plasma Market Report: 2014 Edition" report to their offering. With the swift changes and advancement in biomedical/healthcare technology, the healthcare/pharmaceutical/therapeutic industry is becoming ever more competitive. Also, increasing incidences of health related issues owing to changing lifestyles is augmenting the blood plasma industry's growth. In order to address the rising medical needs related to blood disorders such as autoimmune diseases and liver function impairment among others, market players are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. The report, Global Blood Plasma Market presents different facets of the global blood plasma market with a focus on sub-markets like IVIG, albumin and hemophilia market. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is presented. The market remains highly concentrated and is dominated by a handful of players including CSL, Grifols, Baxter and Octapharma. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. Key Topics Covered: 1. Overview 2. Blood Plasma Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Baxter International Inc. - CSL Limited - Grifols - Octapharma AG For more information visit http://www.researchandmarkets.com/research/v8...obal_blood
BAX: 70.39 (+0.31)
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
BIIB: 391.66 (-0.45), NVS: 102.20 (-0.17)
